🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Gufic Biosciences Limited GUFICBIO NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.gufic.com
Company Profile ↓
₹444.90
+25.45% 1Y
Mkt Cap₹4,461.57 Cr
P/E64.01
P/B6.37
Div. Yield0.02%
52W High₹444.90
52W Low₹273.43
Book Value₹66.31
EPS (TTM)₹6.95

Company Overview

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 11.6% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹944.01 Cr (+15.2% YoY); net profit ₹64.21 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +15.2%, earnings -7.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.6%, profit CAGR -6.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.57%
1 Year:15.15%

Compounded Profit Growth

5 Years:-6.95%
1 Year:-7.80%

Stock Price Performance

1 Year:+25.45%
6 Months:+59.42%
3 Months:+15.05%
1 Month:+10.06%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹273.43 ₹444.90
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)66.02 · Neutral
Price Performance
1M+10.06%
3M+15.05%
6M+59.42%
1Y+25.45%
Valuation vs Sector

P/E of 64.01 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 11.6% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 64.0.
  • Earnings shrank at -6.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
64.01
Industry PE
41.64
Forward P/E est.
69.43
PEG Ratio
-
Book Value
₹66.31
Price to Book
6.37
P/S
4.48
EV/EBITDA
30.14
Dividend Yield
0.02%

Growth (CAGR)

Revenue 5Y
11.57%
Profit 5Y
-6.95%
Revenue (YoY)
15.15%
Earnings (YoY)
-7.80%

Profitability & Returns

ROCE
14.94%
ROE
9.66%
ROA
4.78%
Profit Margin
6.80%
Op Margin
12.77%
Gross Margin
55.38%
EPS (Latest Qtr)
₹2.18
EPS (TTM)
₹6.95

Balance Sheet & Liquidity

Debt/Equity
0.61
Quick Ratio
0.92
Current Ratio
1.55
Debt
₹404.75 Cr
Total Assets
₹1,342.37 Cr
Current Assets
₹802.12 Cr
Working Capital
₹284.27 Cr

Ownership

Promoter Holding
77.50%
Chg in Prom Hold
-0.05%
FII / Inst Holding
3.55%
Chg in FII Hold
0.26%

Financial Snapshot

Enterprise Value
₹4,461.57 Cr
Total Revenue (TTM)
₹944.01 Cr
EBITDA
₹153.99 Cr
Free Cash Flow
₹13.79 Cr
Operating Cash Flow
₹44.97 Cr
Shares Outstanding
₹10.03 Cr
Gross Margin
55.38%
Payout Ratio
1.56%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GUFICBIO Gufic Biosciences Limited NSEPHARMA 444.90 64.01 ₹4,461.57 Cr 0.02% 14.94% 9.66% 11.57% -6.95%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 215.00 Cr202.00 Cr195.00 Cr203.00 Cr204.00 Cr208.00 Cr205.02 Cr223.72 Cr237.05 Cr231.41 Cr251.82 Cr
Cost of Revenue ------89.67 Cr100.77 Cr104.44 Cr101.02 Cr114.95 Cr
Gross Profit ------115.35 Cr122.95 Cr132.62 Cr130.39 Cr136.87 Cr
Operating Expenses 176.00 Cr165.00 Cr161.00 Cr167.00 Cr166.00 Cr174.00 Cr96.82 Cr97.37 Cr102.54 Cr105.10 Cr97.31 Cr
Operating Income 35.00 Cr32.00 Cr30.00 Cr32.00 Cr35.00 Cr29.00 Cr18.53 Cr25.58 Cr30.07 Cr25.29 Cr39.56 Cr
EBITDA 39.00 Cr36.00 Cr34.00 Cr36.00 Cr39.00 Cr34.00 Cr26.77 Cr34.23 Cr39.96 Cr33.77 Cr46.04 Cr
Interest Expense 4.00 Cr3.00 Cr4.00 Cr5.00 Cr5.00 Cr5.00 Cr8.40 Cr9.23 Cr9.58 Cr8.36 Cr9.44 Cr
Pretax Income 31.00 Cr30.00 Cr27.00 Cr28.00 Cr29.00 Cr26.00 Cr10.52 Cr17.27 Cr22.60 Cr17.72 Cr28.95 Cr
Tax Provision 7.75 Cr7.50 Cr7.02 Cr7.28 Cr7.54 Cr6.76 Cr2.81 Cr4.20 Cr5.78 Cr5.30 Cr7.05 Cr
Net Income 23.00 Cr22.00 Cr20.00 Cr21.00 Cr22.00 Cr19.00 Cr7.72 Cr13.07 Cr16.82 Cr12.42 Cr21.90 Cr
Diluted EPS 2.392.222.002.082.171.930.771.301.681.242.18

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -679.75 Cr769.66 Cr819.81 Cr944.01 Cr
Cost of Revenue -340.90 Cr399.29 Cr374.70 Cr421.18 Cr
Gross Profit -338.85 Cr370.36 Cr445.10 Cr522.83 Cr
Operating Expenses -223.52 Cr237.78 Cr331.48 Cr402.32 Cr
Operating Income -115.33 Cr132.58 Cr113.63 Cr120.50 Cr
EBITDA -135.64 Cr147.45 Cr138.32 Cr153.99 Cr
Interest Expense -6.64 Cr14.76 Cr23.11 Cr36.61 Cr
Pretax Income -106.72 Cr115.67 Cr94.14 Cr86.55 Cr
Tax Provision -27.02 Cr29.54 Cr24.49 Cr22.34 Cr
Net Income -79.70 Cr86.14 Cr69.65 Cr64.21 Cr
Diluted EPS 9.898.228.746.95-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -861.16 Cr1,092.54 Cr1,169.36 Cr1,342.37 Cr
Current Assets -464.11 Cr600.48 Cr624.52 Cr802.12 Cr
Cash & Equivalents -28.60 Cr1.14 Cr15.72 Cr62.19 Cr
Inventory -183.46 Cr200.48 Cr216.87 Cr324.47 Cr
Receivables -205.47 Cr329.94 Cr314.61 Cr297.40 Cr
Total Liabilities -513.35 Cr559.98 Cr568.29 Cr677.39 Cr
Current Liabilities -288.21 Cr372.05 Cr387.56 Cr517.85 Cr
Long Term Debt -190.68 Cr153.96 Cr130.50 Cr105.04 Cr
Total Debt -334.19 Cr332.92 Cr336.19 Cr404.75 Cr
Total Equity -347.81 Cr532.56 Cr601.08 Cr664.95 Cr
Shares Outstanding -9.69 Cr10.03 Cr10.03 Cr10.03 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --26.59 Cr-7.46 Cr122.57 Cr44.97 Cr
Investing Cash Flow --190.73 Cr-102.39 Cr-70.78 Cr-30.96 Cr
Financing Cash Flow -234.31 Cr82.38 Cr-37.20 Cr32.46 Cr
Capital Expenditure --187.60 Cr-112.69 Cr-75.53 Cr-31.18 Cr
Free Cash Flow --214.19 Cr-120.15 Cr47.04 Cr13.79 Cr
Net Change in Cash -16.99 Cr-27.46 Cr14.59 Cr46.46 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -49.8%48.1%54.3%55.4%
Operating Margin % -17.0%17.2%13.9%12.8%
Net Margin % -11.7%11.2%8.5%6.8%
ROE % -22.9%16.2%11.6%9.7%
ROCE % -20.1%18.4%14.5%14.6%

Shareholding Pattern

Insiders
77.50%
Institutions
3.55%
Public Float
15.75%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GUFICBIO

Google News Mon, 07 Sep 2026

Gufic Biosciences GUFICBIO 42nd AGM Voting Results - Kalkine India

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxORklQUzVFOGphaUV3c3lzSFN6OE1hMXp1WVV3WVlWalVlWkw2anBzci1iN2RteENfVnFTMTJqT09PaGNac3gwT1FkVzQ3N2xwZllfdk03bWNJc1otTnJ5OG14MWVjTEUzclBNc2g2Xy1GeWxpOU11UWJYdlZUY05PUUhXSmswcjA4LW1QRF…

Google News Wed, 02 Sep 2026

Gufic Biosciences Share Price: Fresh 52-Week High Update - Univest

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPX05ycHp0ajhNU2V1UHUtQmNuZHpiTEQybkVKbUNoTl9Kb0pvbEdoTDVDbnhXNDhET29RemVfVnhjTjJBakdZdnJQUlM0dTRiOWtPMFlJR3p6TlY3SnVWR19fcURvaGx3TlRnZUdablFaU3B1Q09vWnFTck9KcVMtVW5kM3VEZWpUT0dIOE…

Google News Sat, 06 Jun 2026

GUFICBIO Mar 2026 Earnings: Gufic Biosciences Reports EPS of ₹2.05, Revenue at ₹252 Crore; Stock Gains 4.4% - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNbVhta0FpcmJsSUpTMElqWTRPekJOdXVyR2E2OEt1eXVYcklhZFFIV3dQb3BGR0NrVXdtWXVMTm9xbGhKdnZGQ2FXNHpqaFdzRFVzVjNNTUlILVFJaWdCbGFtc0hKQUtXLXpiNDJFbVdoekRQYWxTTHVDRjMwXzNha3l0MWdlSk1CaXdOZX…

Google News Fri, 29 May 2026

Gufic Biosciences Limited announces Annual dividend, payable on October 04, 2026 - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNc3BWQjFaeV91WHZuckUybUFyZkFvUmtDZHpWVTEyN2lzZG5RUWx3MENuNFFMNDZNUEVXQV9MNU9RY2toamRQS2dYeTBObExMMUo1SEVwUDZDZzZQU0lYcWVCa2l0cTBaQ1V6S1piSnVtZ2JsaDZyQllSNDJTNXlldjhGSFFqenNsMHRmeW…

Google News Sat, 13 Jun 2026

GUFICBIO Mar 2026 Earnings: Steady Quarterly Show Amid Pharma Tailwinds - Energy Earnings Report - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNRFZ2OXQyV1QxeE5WM3VSUkQ3cmJIaVR1bjFBNTlIakJrRVFkT3IybkJvRWlyZ1Rka0lxTFFfeEJzNlN4YWRpREJ4d016R1Vyd2oxOXg3WFI1QjNfcmhfU3duZkNOMHhUcnpUM05wbjFLeFFhaHFwUEc1azZDMWlPa1B0bE5FR2pNaWlyYV…

Google News Fri, 05 Jun 2026

GUFICBIO Mar 2026 Earnings: Solid EPS of ₹2.05 Drives 4.4% Stock Gain - Return On Capital - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPX2hUN0VRUlg4aWdpS01KYWJQU1prQXRrTEJaUXVGbllBZHhxbTJRaVd1bkd4LWsxSEhBMU5nMFRzbVRFdUxzNGhidlM5SllIUl9rdHlzOEtkclpBd2E2RUk2Mmd1WE1waFVUcUFHdktNN0MyZ0JqV3B0dnh0WFVNb3Rac1pRc1Vma1lOR3…

GUFICBIO — Frequently Asked Questions

What is the current share price of Gufic Biosciences Limited (GUFICBIO)?

As of 2026-09-08 04:53 IST, Gufic Biosciences Limited (GUFICBIO) trades at ₹444.90 on NSE. Its 52-week range is ₹273.43 to ₹444.90.

What is the market capitalisation of GUFICBIO?

Gufic Biosciences Limited (GUFICBIO) has a market capitalisation of ₹4,461.57 Cr on NSE.

What is the P/E ratio of GUFICBIO?

GUFICBIO trades at a trailing price-to-earnings (P/E) ratio of 64.01. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 6.37.

Does GUFICBIO pay a dividend?

Gufic Biosciences Limited (GUFICBIO) currently offers a dividend yield of 0.02%.

What is the return on equity (ROE) of GUFICBIO?

GUFICBIO has a return on equity (ROE) of 9.66%. Its return on capital employed (ROCE) is 14.94%.

Is GUFICBIO a good stock to buy?

This page provides a data-driven analysis of Gufic Biosciences Limited (GUFICBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space